299 related articles for article (PubMed ID: 12760851)
1. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
[TBL] [Abstract][Full Text] [Related]
5. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
Biswas S; Swift M; Field HJ
Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
[TBL] [Abstract][Full Text] [Related]
6. A novel oral vehicle for poorly soluble HSV-helicase inhibitors: PK/PD validations.
Duan J; Liard F; Paris W; Lambert M
Pharm Res; 2004 Nov; 21(11):2079-84. PubMed ID: 15587931
[TBL] [Abstract][Full Text] [Related]
7. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.
Katsumata K; Chono K; Kato K; Ohtsu Y; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2013 Mar; 57(3):1339-46. PubMed ID: 23274658
[TBL] [Abstract][Full Text] [Related]
9. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.
Biswas S; Sukla S; Goldner T; Field HJ; Kropeit D; Paulsen D; Welbers A; Ruebsamen-Schaeff H; Zimmermann H; Birkmann A
Antimicrob Agents Chemother; 2014 Jul; 58(7):3843-52. PubMed ID: 24752278
[TBL] [Abstract][Full Text] [Related]
11. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo.
Himaki T; Masui Y; Chono K; Daikoku T; Takemoto M; Haixia B; Okuda T; Suzuki H; Shiraki K
Antiviral Res; 2012 Feb; 93(2):301-304. PubMed ID: 22155691
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis.
Quenelle DC; Birkmann A; Goldner T; Pfaff T; Zimmermann H; Bonsmann S; Collins DJ; Rice TL; Prichard MN
Antiviral Res; 2018 Jan; 149():1-6. PubMed ID: 29113740
[TBL] [Abstract][Full Text] [Related]
14. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
15. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
[TBL] [Abstract][Full Text] [Related]
17. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir.
Field HJ; Huang ML; Lay EM; Mickleburgh I; Zimmermann H; Birkmann A
Antiviral Res; 2013 Nov; 100(2):297-9. PubMed ID: 24021190
[TBL] [Abstract][Full Text] [Related]
18. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
19. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
[TBL] [Abstract][Full Text] [Related]
20. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
